Skip to main content

Table 2 Baseline characteristics (safety population)a

From: Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm

Characteristic Placebo (N = 97) Bremelanotide All pooled (N = 394)
0.75 mg (N = 100) 1.25 mg (N = 99) 1.75 mg (N = 98)
Age (years), mean (SD) 37.0 (7.7) 37.6 (7.8) 35.7 (7.2) 37.0 (7.6) 36.9 (7.6)
Race, n (%)
White 75 (77) 71 (71) 65 (66) 70 (71) 281 (71)
Black 19 (20) 25 (25) 32 (32) 23 (23) 99 (25)
Other 3 (3) 4 (4) 2 (2) 5 (5) 14 (3)
Diagnosis, n (%)
FSAD 4 (4) 3 (3) 3 (3) 2 (2) 12 (3)
HSDD 24 (25) 20 (20) 24 (24) 24 (24) 92 (23)
Mixed 69 (71) 77 (77) 72 (73) 72 (73) 290 (74)
Menses frequency regular, n (%) 72 (74) 75 (75) 86 (87) 79 (81) 312 (79)
Used oral contraception ≤ 30 days before screening, n (%) 12 (12) 15 (15) 11 (11) 15 (15) 53 (13)
  1. FSAD = female sexual arousal disorder; HSDD = hypoactive sexual desire disorder; SD = standard deviation
  2. aAll participants exposed to study drug